Oncology PracticeBladder cancer indication withdrawn for durvalumabMarch 1, 2021Genitourinary CancerGynecologic Cancer
Hematology NewsJ&J COVID-19 vaccine wins unanimous backing of FDA panelFebruary 27, 2021COVID-19 Updates
Oncology PracticeFDA approves cemiplimab-rwlc for NSCLC with PD-L1 expressionFebruary 24, 2021Lung Cancer
Hematology NewsVariants spur new FDA guidance on COVID vaccines, tests, drugsFebruary 23, 2021COVID-19 Updates
Oncology PracticeFDA approves first drug that protects against chemo-induced myelosuppressionFebruary 16, 2021Lung Cancer
Hematology NewsSome COVID-19 vaccine reactions could be pseudoallergic, experts sayFebruary 10, 2021COVID-19 Updates
Oncology PracticeCemiplimab approved for locally advanced, metastatic basal cell carcinomaFebruary 10, 2021Nonmelanoma Skin Cancer
Hematology NewsFDA alert confirms heart and cancer risks with tofacitinib (Xeljanz)February 5, 2021PediatricsGastroenterologyThrombosisGastrointestinal Cancer
Oncology PracticeFDA grants MET inhibitor tepotinib accelerated approval for NSCLCFebruary 4, 2021Lung Cancer
Hematology NewsAnaphylaxis cases after COVID-19 vaccine rising but still rare: CDCJanuary 7, 2021COVID-19 Updates
Hematology NewsCDC issues COVID-19 vaccine guidance for underlying conditionsDecember 29, 2020COVID-19 Updates
Hematology NewsModerna’s COVID-19 vaccine deemed ‘highly effective,’ but further studies neededDecember 23, 2020COVID-19 Updates
